AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitionsProactive Investors • 12/07/21
AstraZeneca agrees licensing deal with California biotech worth up to US$3.5bnProactive Investors • 12/07/21
Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?The Motley Fool • 12/04/21
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer CareBusiness Wire • 12/03/21
Scientists identify reaction that may cause rare blood clots after AstraZeneca Covid vaccineCNBC • 12/02/21
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast CancerBusiness Wire • 11/30/21
Oxford University says it can quickly update AstraZeneca's COVID-19 vaccineProactive Investors • 11/30/21
Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDAMarket Watch • 11/30/21
AstraZeneca boss suggests Europe's Covid-19 spike linked to vaccine snubProactive Investors • 11/23/21
Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology TherapeuticsBusiness Wire • 11/19/21
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerBusiness Wire • 11/18/21